SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,281. The last known price of Bitcoin is 71,086.72423286 USD and is down -3.89 over the last 24 hours. It is currently trading on 12779 active market(s) with $28,515,435,687.36 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and break below a major psychological level have dominated discussion, with traders pointing to leveraged-position liquidations as adding to the pressure. The community is split between expectations of further downside amid risk-off and rate concerns and calls to buy an oversold dip.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas is drawing attention as its Phase 3 REGAL trial of GPS reaches final analysis after the 80th event, with topline results expected in November. Traders celebrated an after-hours jump and speculated about a data leak or short covering, while skeptics stressed that the results are still unknown and managements positive language does not establish success.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

A widespread Microsoft 365 outage disrupted Outlook, Teams, Copilot and other services, prompting complaints about business disruption and concern that the incident could damage trust. Traders debated whether it was a technical failure or a cyberattack, though hacking claims remained speculation, and many questioned why the shares held up amid the disruption.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs decision to remove Strategy from its indexes is dominating discussion, with traders concerned that passive-fund selling could pressure the stock and make its Bitcoin-funding model harder to sustain as Bitcoin weakens. Others argue the exclusion is already priced in or that Bitcoins decline is the bigger driver, while some holders continue buying the dip.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRX is drawing attention after a sharp selloff tied to a Q3 revenue miss and the lack of detailed guidance, with traders debating cash burn, possible dilution, and managements communication. Optimism about the BCG-naive trial results, a planned FDA filing, expanded Anktiva access, and sepsis studies is countered by concern that commercial growth may not keep pace with expectations.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,212,724.47747979. The last known price of Ethereum is 2,011.23339821 USD and is down -2.26 over the last 24 hours. It is currently trading on 14326 active market(s) with $10,433,558,649.69 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereum is drawing attention amid a sharp crypto-market selloff, with traders pointing to inflation and hawkish rate expectations, Bitcoin weakness, and leveraged-position liquidations as pressure on prices. The community is divided between bearish calls for further losses and buyers treating the decline as an oversold opportunity, while key support levels are closely watched.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels planned prostate-cancer BLA filing was pushed to mid-2027 amid ongoing FDA discussions over assay refinement, triggering a sharp selloff and widespread criticism of managements communication and credibility. Traders disagree on whether this is a fixable manufacturing and regulatory delay that leaves the clinical data intact or a sign of deeper execution risk, with dilution also a concern.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.03439229 USD and is down -2.16 over the last 24 hours. It is currently trading on 1895 active market(s) with $1,786,076,895.36 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

A broad crypto selloff has XRP sliding toward key support, with traders pointing to Bitcoin-led market weakness, inflation and rate-hike concerns, and leveraged liquidations. The community is split between holders accumulating the dip and bearish traders warning of more downside, while some also cite Ripple-related token supply and fading regulatory hopes.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs reported departure as CEO, with CFO Colette Kress taking over as interim CEO, is driving concern about Nvidias leadership transition and contributing to a sharp selloff. Traders are divided between viewing Huang as essential to the company and treating the decline as an overreaction, while some also speculate about possible China chip-export scrutiny without confirmation.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Bitcoins sharp decline and broader weakness in crypto-linked stocks are weighing on Coinbase, with traders focused on its repeated lows and whether the selloff will continue. The discussion is predominantly bearish, though some see the stock as oversold or holding support and expect a rebound if crypto stabilizes.

statis crypto Watchlist

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

New Strong Buy Stocks for November 12th

PANL, CBRL, KROS, NEPH and LRN have been added to the Zacks Rank #1 (Strong Buy) List on November 12, 2026.

Down 21% in 4 Weeks, Here's Why Keros Therapeutics (KROS) Looks Ripe for a Turnaround 

Keros Therapeutics (KROS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Keros Therapeutics, Inc. (KROS) Q3 Earnings and Revenues Surpass Estimates

Keros Therapeutics (KROS) delivered earnings and revenue surprises of +172.92% and +197.47%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday

A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on MondayPR NewswireNEW YORK, Oct. 20, 2026 NEW YORK, Oct. 20, 2026 /PRNewswire/ -- Market Updates News Commentary- Two unrelated...

Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?

Reblozyl's strong growth is helping Bristol Myers offset declining legacy drug sales, with new indications offering further upside.

KROS Begins Dosing in Phase II Study With Rinvatercept in DMD

Keros Therapeutics begins dosing in a phase II study of rinvatercept in DMD patients, with initial data expected in the first half of 2027.

Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?

Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak

Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.

Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?

Keros' rinvatercept pipeline offers upside, but zero quarterly revenue, clinical risk and a premium valuation make the stock a cautious bet.

KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus

Keros posts a wider Q2 loss as revenues fall to zero, while cash runway into H1 2028 and rinvatercept pipeline milestones keep attention on future growth.

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.

Keros Therapeutics Inc

Keros Therapeutics Adopts Defense Strategy Against Potential Hostile Takeover, Explores Sale: Retail’s Overjoyed

Equity

Bearish Sentiment

Shares of Keros Therapeutics, Inc. (KROS) traded 14% higher on Thursday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.kerostx.com/news-releases/news-release-details/keros-therapeutics-announces-review-strategic-alternatives">adopted</a> a poison pill plan to fend off hostile takeovers by a number of investors that have rapidly accumulated a significant number of shares in the firm.The defense strategy, a limited-duration stockholder rights plan, will reduce the likelihood that a hostile group gains control of Keros through open-market accumulation without paying all stockholders an appropriate control premium.As per the plan, if any entity acquires ownership of 10% or more, or 15% in the case of passive institutional investors, of Keros’ outstanding common stock in a transaction not approved by the Board, other shareholders can purchase additional shares at a discount.The company adopted the plan after a number of investors who accumulated the company’s common stock indicated a desire to gain control over the firm. This included an individual investor who informed the company that it holds 11.2% of Keros’ outstanding common stock as of April 6, 2025. The company did not name the investor.Keros said that its board has also decided to initiate a formal review process to evaluate strategic alternatives to maximize stockholder value for the company.A committee will consider a range of strategic alternatives including the sale of the company or other business combination transaction, continued investment in its pipeline, or return of excess capital to stockholders.The company added that there is no assurance the review will lead to the company pursuing a transaction.On Stocktwits, retail sentiment around Keros jumped from ‘neutral’ to ‘extremely bullish’ while message volume rose from ‘low’ to ‘extremely high’ over the past 24 hours.<figure class="image"><img style="aspect-ratio:647/151;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_10_at_11_27_14_AM_png_386737346f.webp" alt="KROS's Sentiment Meter and Message Volume as of 11:30 a.m. ET on April 10, 2025 | Source: Stocktwits" width="647" height="151"><figcaption>KROS's Sentiment Meter and Message Volume as of 11:30 a.m. ET on April 10, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/KROS">KROS shares</a> are down by about 26% year-to-date and 81% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/polestar-q1-sales-jump-76-percent-on-newer-models/chfYiCFRbBr">Polestar Q1 Sales Jump 76% On Newer Models: Retail Sentiment Brightens</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

The company said the plan aims to reduce the likelihood of any entity or person gaining control of Keros through open-market accumulation without paying all stockholders an appropriate control premium.

iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

Nvidia ($NVDA) is moving lower after Jensen Huang resigned as CEO. Are you buying the dip?

Stocktwits

) is moving lower after Jensen Huang resigned as CEO. Are you buying the dip?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	-$1.63	--	--	N/A
Q3 '26	-$0.94	$0.70	174.53%	BEAT
Q2 '26	-$1.39	-$1.45	-4.32%	MISSED
Q1 '26	-$1.02	-$1.21	-18.30%	MISSED
Q4 '25	-$0.70	-$0.86	-23.36%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

KROS Earnings

Latest Earnings Results: Q3 '26

Historical Earnings